This study lays a strong foundation for progressing the use of HPDGS inhibitors such as PK007, which specifically inhibit PGD2 and reduce inflammation, as a viable therapeutic approach for DMD. The gene discussed is HPGDS; the disease is Duchenne muscular dystrophy.